| Pathway/Process | Role of ASS1 | Tissue Context | Key Interacting Enzymes/Proteins | References |
|---|---|---|---|---|
| Urea cycle (ammonia detoxification) | Catalyzes the ATP-dependent condensation of citrulline and aspartate to form argininosuccinate, a rate-limiting cytosolic step of the urea cycle that supports ammonia disposal as urea. | Highest functional importance in liver, especially periportal hepatocytes; also relevant in inherited urea-cycle disease. | ASL, CPS1, OTC, ARG1 | (pqac-00000001, pqac-00000018, pqac-00000039, pqac-00000040) |
| De novo arginine biosynthesis | Produces argininosuccinate for subsequent conversion to arginine, supporting endogenous arginine synthesis from citrulline and aspartate. | Broadly expressed across tissues; especially important in kidney for systemic arginine production and in liver for integrated nitrogen metabolism. | ASL, citrulline supply pathways | (pqac-00000017, pqac-00000021, pqac-00000024) |
| Citrulline-NO recycling cycle | Regenerates arginine from citrulline to sustain nitric oxide production; acts as a key control point in the citrulline-NO cycle. | Endothelial and other NO-producing cells; also relevant in liver injury contexts with NOS2 induction. | NOS isoforms, ASL, caveolae-associated partners | (pqac-00000018, pqac-00000020, pqac-00000021) |
| Aspartate competition/pyrimidine synthesis | Consumes aspartate for argininosuccinate synthesis; when ASS1 is lost or silenced, aspartate is redirected toward pyrimidine/nucleotide biosynthesis, promoting proliferation. | Especially prominent in ASS1-low or ASS1-silenced cancers. | Pyrimidine synthesis network, p53-linked metabolic regulators | (pqac-00000019, pqac-00000022, pqac-00000031, pqac-00000050) |
| AMPK/lipid metabolism linkage | Couples ureagenesis and amino-acid catabolism to hepatic AMPK activation and lipid oxidation; ASS1 knockdown suppresses ureagenesis and AMPK signaling. | Liver, particularly fasting/protein catabolism metabolic states. | AMPK and downstream hepatic lipid metabolism effectors | (pqac-00000023) |
| Nuclear DNA damage response (p53/SMARCC1) | After DNA damage, ASS1 accumulates in nucleus and cytosol; in nucleus it works with ASL to generate fumarate, promotes SMARCC1 succination, alters SWI/SNF complex behavior, and modulates p53-regulated cell-cycle transcription. | Demonstrated in cultured human cancer cells and supported by liver nuclear studies; relevant to tumor suppression and genome maintenance. | p53, IPO7, ASL, SMARCC1, SNF5, SWI/SNF chromatin-remodeling complex | (pqac-00000025, pqac-00000026, pqac-00000028, pqac-00000030, pqac-00000050, pqac-00000051) |
| Circadian regulation of ureagenesis (CLOCK acetylation) | Undergoes rhythmic CLOCK/BMAL1-dependent acetylation at K165/K176, which inhibits ASS1 activity and drives circadian oscillation of ureagenesis and arginine-cycle metabolites. | Hepatocytes and mouse liver. | CLOCK, BMAL1, HDACs | (pqac-00000042, pqac-00000043, pqac-00000044, pqac-00000046, pqac-00000047, pqac-00000049) |


*Table: This table summarizes the major metabolic pathways and biological processes involving human ASS1, including canonical urea-cycle functions and newer non-canonical roles in nuclear DNA-damage signaling and circadian regulation. It is useful for functional annotation because it links ASS1 biochemistry to tissue context and interacting partners.*